Highly carcinogenic asbestos found exposed to air at Noto quake-hit hotel in central Japan
SUZU, Ishikawa -- Crocidolite, a highly carcinogenic type of asbestos, has been found exposed at a hotel damaged by the January 2024 Noto Peninsula earthquake and subsequent heavy rains in September, risking airborne dispersal of its fibers, according to a nonprofit organization survey.
An on-site survey by the Tokyo-based nonprofit Asbestos Center identified exposed crocidolite, also known as blue asbestos, at Hotel Kairakuso in Suzu, Ishikawa Prefecture. Part of the asbestos material had broken off and fallen to the ground, increasing the likelihood that fibers dispersed into the air.
Many volunteers have been assisting with recovery efforts at the hotel and surrounding areas, including earth and sand removal. Asbestos Center Secretary-General Fuyushi Nagakura emphasized, "Measures should immediately be taken to prevent the dispersal of the substance and inform volunteers of the danger."
In the powerful earthquake that struck the Noto Peninsula in January 2024, walls at Hotel Kairakuso partially collapsed. It was damaged further by mudslides triggered by torrential rains that September, with sediment flowing into the hotel's three buildings along a nearby river.
In an investigation in April this year, the Asbestos Center found that bluish fireproof material had been used in the beams and upper portions of columns in one of the three buildings, located farthest upstream, where sediment flows had created a large hole in a wall. The survey discovered numerous locations where the material appeared to have been scraped off or dislodged by sediment, with five lumps of the substance, roughly 2 to 10 centimeters in diameter, found on the ground. Analysis conducted by a specialized institute in Tokyo confirmed the material as crocidolite.
Given that many volunteers have assisted in removing sediment from the three-story steel-framed building, there is concern they may have been exposed to airborne fibers. Sediment potentially containing crocidolite remains piled near a national route in front of the hotel, where several volunteers were spotted working during the recent survey.
According to the hotel's operator, the Ishikawa Prefectural Government notified them of asbestos presence following the earthquake, prompting repairs of the collapsed walls to prevent dispersal. However, the hotel owner died in mudslides caused by the heavy rains in September. Additionally, sediment accumulation of about 2 meters outside the building hindered the hotel operator from becoming fully aware of wall damages and asbestos exposure until approximately March this year, after the sediment was removed.
Nagakura warned, "Crocidolite, which should completely be sealed off, was exposed without any covering. The sediment, entrapping the crocidolite, flowed into the buildings downstream as well." Regarding ongoing volunteer activities, he added, "They should warn volunteers to stay away until measures are taken."
An Ishikawa Prefectural Government representative told the Mainichi Shimbun, "We are looking into the circumstances on-site. Considering the possibility of asbestos being present, we have asked the hotel to take steps to prevent dispersal and stop accepting volunteers. We will consider necessary actions based on the survey."
Asbestos is an extremely fine fibrous mineral, as thin as a few thousandths of a human hair. When inhaled, asbestos fibers can lead to serious health conditions including mesothelioma -- a type of malignant cancer affecting the tissue lining internal organs -- or lung cancer, typically appearing after a latency period of approximately 20 to 60 years. Three common asbestos varieties are chrysotile (white asbestos), amosite (brown asbestos) and crocidolite, with crocidolite considered particularly hazardous. In previous documented cases, numerous residents near factories using crocidolite later developed asbestos-related illnesses.
(Japanese original by Hidetoshi Oshima, Osaka Editorial Division)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Japan Times
17 hours ago
- Japan Times
Female Underweight/Undernutrition Syndrome to be classified disorder
The Japan Society for the Study of Obesity announced in April that it will recognize a new health disorder affecting women, to be classified as Female Underweight/Undernutrition Syndrome, or FUS, linked to being underweight and suffering undernutrition. According to the group, known as JASSO, 20% of women in their 20s in Japan are underweight, one of the highest rates among developed countries. It plans to establish diagnostic criteria for the syndrome as part of efforts to promote early detection and prevention. The trend toward thinness among young women in Japan has become increasingly pronounced in recent years. According to the health ministry's 2023 National Health and Nutrition Survey, 12.0% of women aged 20 and over were classified as underweight on the basis of their body mass index, or BMI, a standard measure used to assess weight status. By contrast, only 4.4% of men in the same age group were considered underweight. By age group, 24.4% of women in their 20s and 17.9% of women in their 30s were underweight. The calculation of BMI involves dividing people's weight in kilograms by the square of their height measured in meters. According to JASSO guidelines, a BMI of 22 is considered the standard, with a reading below 18.5 classified as "thin" or "underweight," between 18.5 and below 25 as "normal weight," and 25 and above as "obese." JASSO defines FUS as a condition in which extreme weight loss and undernutrition in women age from 18 up to menopause leads to a range of health issues. These include decreased bone density or osteoporosis, irregular menstrual cycles, muscle weakness, anemia, fatigue, depression and metabolic abnormalities. FUS can lower quality of life over the medium to long term and increase the risk of frailty, declines in mental and physical vitality and other aspects of life often associated with aging, according to the society. Explaining a major factor contributing to the rise of FUS, the society noted that "the value equating thinness with beauty has become widespread, leading many, especially young women, to engage in weight-loss behaviors such as restricting food intake." In 2023, My Well Body Kyogikai, a group dedicated to women's health issues, conducted an online survey of 1,000 women in Japan between the ages of 16 and 23. The results revealed that about 20% of underweight women, and more than half of women with a normal weight, considered themselves to be "fat." Additionally, 16% of underweight women and 48% of women with a normal weight said they wanted to lose more weight. The most common motivation cited was the desire to feel more confident about themselves. The survey results also suggest that social media platforms such as Instagram, YouTube and TikTok may be influencing a range of weight loss behaviors. In recent years, the use of medications originally developed for the treatment of obesity and diabetes has surged among individuals seeking to lose weight, a trend that has raised concerns among health experts. Such drugs typically work by suppressing appetite or increasing the excretion of sugar through urine, leading to weight loss as a secondary effect. There are worries about health risks, however, including acute pancreatitis and other serious side effects. Wataru Ogawa, executive director of JASSO, said, "Medical systems and public health measures (in Japan) have historically focused on combating obesity, while systematic approaches to address underweight and undernutrition have been insufficient." He emphasized that the organization plans to establish diagnostic criteria and promote educational initiatives, following the collection of relevant medical evidence.
NHK
18 hours ago
- NHK
Scientists in race to fight drug resistance
What happens if antibiotics stop working? The scientific world describes this threat to global health as antimicrobial resistance, or AMR. One study warns more than 39 million people could die by 2050 unless further measures are taken. Scientists from Japan and the United Kingdom have teamed up in the race to find a solution. Dr. Tamura Tsuyoshi sees plenty of patients at his Tokyo clinic who present with the common cold. He does not prescribe antibiotics for them because the drugs are ineffective against a virus. Nevertheless, some patients want them. "There are patients who feel secure when they take antibiotics," he says, adding, "I cannot refuse them unless I completely rule out a bacterial infection." Dr. Tamura Tsuyoshi of Tamura Clinic in Tokyo Tamura runs tests to identify the cause of his patients' illnesses to help determine the best treatment. He makes a conscious effort to avoid over-prescribing antibiotics. Bacteria are constantly evolving: changing their membranes to keep drugs out, expelling drugs, or altering drugs' targets to render antibiotics ineffective. The overuse and inappropriate use of antibiotics are key drivers in accelerating that process – making AMR a global problem. Core of modern medicine Dr. Matsunaga Nobuaki is an AMR expert at the Japan Institute for Health Security. He warns that if antibiotics stop working, the effects would be far-reaching. Dr. Matsunaga Nobuaki is an AMR expert at the Japan Institute for Health Security. "People need to realize that antibiotics are the infrastructure behind all modern medical care," he says. "If people can't use them, then cancer patients are at risk, not just from cancer, but infectious diseases. Also, doctors need to consider the risk of resistant bacteria when they do surgery." Patients undergoing surgery are routinely administered antibiotics to prevent infection, including women giving birth by cesarean section. Cancer patients whose immune systems are weakened by chemotherapy are also at risk. Developing new antibiotics While the appropriate use of antibiotics is essential to tackle AMR, there is also a need for new antibiotics to replace those that have become ineffective. According to the World Health Organization, the matter is urgent. Research institutions in both Japan and the UK are teaming up to try and meet this challenge. Dr. Alicia Demirjian is an infectious disease specialist from the UK Health Security Agency who visited Japan in February. The country used to be a medical powerhouse back in the 1980s, and she says it has the potential to reclaim that mantle. Dr. Alicia Demirjian, UK Health Security Agency, fourth from left, in Japan "I think we can rely on some of the science that has been done before," she says. "The fact that the public is aware that there have been some very strong Japanese scientists to build on this and bring back the notion that AMR is an important topic, infectious diseases are an important topic, and we know it is possible within Japan." Dr. Alicia Demirjian, UK Health Security Agency Matsunaga and Demirjian visited Japanese institutions that could make a difference, including Kitasato University in Tokyo. The laboratories there have collected soil from across Japan, isolating hundreds of microorganisms with the goal of seeing if any can be used to make new drugs. A collaboration is now underway with the University of Warwick in the UK. A researcher outlines the laboratory work to Matsunaga, third from left, and Demirjian, fourth from left. Kitasato University's President Sunazuka Toshiaki says while the basic research is underway, finding new compounds with potential is a long, difficult process. "The project offers us a good chance, and I think we can have a win-win relationship," he says of the joint enterprise. Private companies are also involved. Pharmaceutical firm Shionogi is behind one of the latest antibiotics that works against drug-resistant bacteria. It was approved in the United States in 2019. With approval of the antibiotic's safety and efficacy, it is now used in 26 countries and regions. Shionogi vice chairperson Sawada Takuko told Matsunaga and Demirjian that many companies around the world do not work on developing antibiotics because it is simply not profitable. Sawada Takuko, Vice Chairperson of the Board, Shionogi Sawada notes some fledgling drug companies have gone bankrupt even after the successful development and launch of products to market, which risks discouraging progress. "If young researchers saw that situation, why can they choose infectious disease area for their research?" she says. Sawada is calling for more government support to sustain the development of new antibiotics. Matsunaga and Demirjian meet with Sawada. Market challenges In countries like Japan and the UK, governments are allocating funds towards the production of new medicines to tackle AMR. Japan is investing 1.3 billion yen or more than $9 million annually as incentives for firms that have launched drugs targeting a specific type of drug resistant bacteria onto the market. The way in which new antibiotics are introduced ― and saved for use at appropriate times ― makes it a long, expensive process. Overusing newly developed drugs would feed into the existing problem. Raising awareness At a workshop hosted by Matsunaga and Demirjian, participants discussed how to raise public awareness of AMR. "I think we all now have some homework," says Demirjian. "We have to go back within our respective organizations, continue the advocacy work that needs to be done and then continue to touch base every now and then so that we can keep progressing the work." Reducing AMR's death toll The estimated number of deaths associated with AMR was nearly five million in 2019. Last year, world leaders at the United Nations committed to reducing that total by 10 percent by 2030. For now, the WHO wants countries to develop and implement their own AMR action plans. But lower- and middle-income countries have difficulty funding the required initiatives, and also struggle to get testing kits and appropriate medicines. Inadequate sanitation on top of those issues creates a perfect storm for the growth of resistant bacteria. AMR used to be called a "silent pandemic." Many researchers have dropped that name now that it has become an urgent problem with grave consequences.
Asahi Shimbun
a day ago
- Asahi Shimbun
Wanted: Poop donors in Yamagata for bacteria study
This 10-course 'shojin' vegetarian meal served at Mount Haguro Sanrojo Saikan, a shrine lodging at one of the Three Sacred Mountains of Dewa in Tsuruoka, Yamagata Prefecture, on Sept. 18, 2024, contains dishes wherein local crop varieties are used, such as Tonojima cucumbers boiled down in soy sauce, far right in the middle row, and taro stalks dressed with miso and ground sesame, far right in the bottom row. (Koji Shimizu) TSURUOKA, Yamagata Prefecture--Shonai residents enjoy an opulent culinary culture in the region that has taken root in helping them lead healthier lifestyles. Many residents of the area are ingesting a broad variety of dietary fibers, which helps increase the diversity of intestinal bacteria, making their stool samples vital resources for researchers. A facility designed exclusively for stool donations was set up recently in this northeastern city, by a business venture with roots in Juntendo University and other institutions. The collection center is calling for donors who may have a useful flora of intestinal bacteria in their bowels. If donors qualify, they will get paid for their troubles. The poop to be donated at the facility in Tsuruoka, Yamagata Prefecture, the first of the sort in Japan, will be used to develop drugs for treating diseases including ulcerative colitis, which is designated as intractable. The Tsuruoka stool donation room, which opened April 24 in a science park in the city, is operated by Metagen Therapeutics Inc. The Tsuruoka-based startup has its origins in Juntendo University, Keio University and the Institute of Science Tokyo. 'The help of citizens matters more than anything else for making sure that intestinal bacteria that are rooted in Tsuruoka's culinary culture will be delivered to the rest of the world,' Metagen Therapeutics CEO Taku Nakahara told an opening ceremony on April 24. 'We hope to be working with you all to save patients across the globe.' The collection facility has three restrooms, designed specifically for stool donations and with no water flush functions, and a lounge area, where donors can make themselves at home until they are ready to move their bowels. Human intestinal bacterial flora is believed to contain about 1,000 species, which work, in keeping an exquisite balance, to maintain the host's health, including by promoting digestion and defecation and by adjusting immunity. Overuse of antibacterial agents (antibiotics) and an excessive intake of animal protein and fat can cause a loss of healthy intestinal bacteria and give rise to various diseases, Metagen Therapeutics officials said. 'SUPERB' INTESTINAL FLORA Therapies that involve transplanting healthy intestinal bacteria into patients to improve their intestinal environment are currently being studied in Japan. Metagen Therapeutics has been working on the research and development of drugs that are made from feces. A search for healthy intestinal florae led the company's officials to the Shonai area, including Tsuruoka, in the northwest of Yamagata Prefecture. The foods eaten here include the 'shojin' vegetarian cuisine of the Three Sacred Mountains of Dewa, which draws on edible wild plants, mushrooms and other food ingredients of the season, as well as the use of locally available crop varieties. Hopes for the availability of healthy and 'superb' intestinal florae prompted the selection of the Shonai area. The local community has been cooperative toward the project. A local restaurant, for example, has prepared, on a trial basis, dishes that are friendly to the intestinal flora. Residents also responded positively during an explanatory meeting held in advance, officials of the startup said. The Tsuruoka stool donation room is the first facility in Japan that is specially designed for the purpose, even though Juntendo University Hospital in Tokyo had already been accepting stool donations, the company officials added. 5,000 YEN PER DONATION Eligible for stool donations are residents of the Shonai area aged between 18 and 65. Prospective donors have to sign up on a Web page before they take an online health checkup and undergo an interview with a doctor, a blood test and a stool test at the Tsuruoka Municipal Shonai Hospital. Those who qualify are registered as donors and are asked to visit the facility regularly. They are entitled to receive up to 5,000 yen ($34) in 'cooperation money' per stool donation. The Metagen Therapeutics officials said they have set the target of having somewhere between several dozen and 100 registered donors by year-end. Intestinal bacteria will be extracted from the donated poop and processed for preservation at dedicated equipment before being shipped to a drug manufacturing facility in Kawasaki, Kanagawa Prefecture, to make medicines. Metagen Therapeutics is currently engaged in the research and development of poop-derived drugs for treating ulcerative colitis, gastrointestinal cancer and Parkinson's disease. The company is planning to start clinical tests for an ulcerative colitis drug in Japan and the United States in 2026, and is hoping to have the drug approved for use and released for sale in 2032. The world's first poop-derived preparation was approved for use in Australia in 2022. The United States has also approved similar drugs.
